Send us Feedback

Eli Lilly and Company (LLY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

LLY » Topics » Legal Proceedings Described in Managements Discussion and Analysis

This excerpt taken from the LLY 10-K filed Feb 22, 2010.
Legal Proceedings Described in Management’s Discussion and Analysis
See Item 7, “Management’s Discussion and Analysis—Legal and Regulatory Matters,” for information on various legal proceedings, including but not limited to:
 
  •  The U.S. patent litigation involving Alimta, Cymbalta, Evista, Gemzar, Strattera, and Xigris
 
  •  The patent litigation outside the U.S. involving Zyprexa
 
  •  The various federal and state investigations relating to our sales, marketing, and promotional practices
 
  •  The Zyprexa product liability and related litigation, including claims brought on behalf of state Medicaid agencies and private healthcare payers
 
That information is incorporated into this Item by reference.
 
These excerpts taken from the LLY 10-K filed Feb 27, 2009.
Legal Proceedings Described in Management’s Discussion and Analysis
 
See Part II, Item 7, “Management’s Discussion and Analysis − Legal and Regulatory Matters,” for information on various legal proceedings, including but not limited to:
 
  •   The U.S. patent litigation involving Alimta, Cymbalta, Evista, Gemzar, and Xigris
 
  •   The patent litigation outside the U.S. involving Zyprexa


-14-

 

 
  •   The investigations by the U.S. Attorney for the Eastern District of Pennsylvania and various state attorneys general relating to our U.S. sales, marketing, and promotional practices
 
  •   The Zyprexa product liability and related litigation, including claims brought on behalf of state Medicaid agencies and private healthcare payers
 
That information is incorporated into this Item by reference.
 
Legal
Proceedings Described in Management’s Discussion and
Analysis


 



See Part II, Item 7, “Management’s
Discussion and Analysis − Legal and Regulatory
Matters,” for information on various legal proceedings,
including but not limited to:


 


























  •  
The U.S. patent litigation involving Alimta, Cymbalta,
Evista, Gemzar, and Xigris
 
  •  
The patent litigation outside the U.S. involving Zyprexa





-14-




 





 


























  •  
The investigations by the U.S. Attorney for the Eastern
District of Pennsylvania and various state attorneys general
relating to our U.S. sales, marketing, and promotional
practices
 
  •  
The Zyprexa product liability and related litigation, including
claims brought on behalf of state Medicaid agencies and private
healthcare payers


 



That information is incorporated into this Item by reference.


 




These excerpts taken from the LLY 10-K filed Oct 21, 2008.
Legal Proceedings Described in Management’s Discussion and Analysis
 
See Part II, Item 7, “Management’s Discussion and Analysis – Legal and Regulatory Matters,” for information on various legal proceedings, including but not limited to:
 
  •   The U.S. patent litigation involving Evista, Gemzar, Strattera, and Xigris
 
  •   The patent litigation outside the U.S. involving Zyprexa
 
  •   The investigations by the U.S. Attorney for the Eastern District of Pennsylvania and various state attorneys general relating to our U.S. sales, marketing, and promotional practices
 
  •   The Zyprexa product liability and related litigation, including claims brought on behalf of state Medicaid agencies and private healthcare payers
 
That information is incorporated into this Item by reference.
 
Legal
Proceedings Described in Management’s Discussion and
Analysis


 



See Part II, Item 7, “Management’s
Discussion and Analysis – Legal and Regulatory
Matters,” for information on various legal proceedings,
including but not limited to:


 














































  •  
The U.S. patent litigation involving Evista, Gemzar,
Strattera, and Xigris
 
  •  
The patent litigation outside the U.S. involving Zyprexa
 
  •  
The investigations by the U.S. Attorney for the Eastern
District of Pennsylvania and various state attorneys general
relating to our U.S. sales, marketing, and promotional
practices
 
  •  
The Zyprexa product liability and related litigation, including
claims brought on behalf of state Medicaid agencies and private
healthcare payers


 



That information is incorporated into this Item by reference.


 




These excerpts taken from the LLY 10-K filed Feb 29, 2008.
Legal Proceedings Described in Management’s Discussion and Analysis
 
See Part II, Item 7, “Management’s Discussion and Analysis – Legal and Regulatory Matters,” for information on various legal proceedings, including but not limited to:
 
  •   The U.S. patent litigation involving Evista, Gemzar, Strattera, and Xigris
 
  •   The patent litigation outside the U.S. involving Zyprexa
 
  •   The investigations by the U.S. Attorney for the Eastern District of Pennsylvania and various state attorneys general relating to our U.S. sales, marketing, and promotional practices
 
  •   The Zyprexa product liability and related litigation, including claims brought on behalf of state Medicaid agencies and private healthcare payers
 
That information is incorporated into this Item by reference.
 
Legal
Proceedings Described in Management’s Discussion and
Analysis


 



See Part II, Item 7, “Management’s
Discussion and Analysis – Legal and Regulatory
Matters,” for information on various legal proceedings,
including but not limited to:


 














































  •  
The U.S. patent litigation involving Evista, Gemzar,
Strattera, and Xigris
 
  •  
The patent litigation outside the U.S. involving Zyprexa
 
  •  
The investigations by the U.S. Attorney for the Eastern
District of Pennsylvania and various state attorneys general
relating to our U.S. sales, marketing, and promotional
practices
 
  •  
The Zyprexa product liability and related litigation, including
claims brought on behalf of state Medicaid agencies and private
healthcare payers


 



That information is incorporated into this Item by reference.


 




This excerpt taken from the LLY 10-K filed Feb 28, 2007.
Legal Proceedings Described in Management’s Discussion and Analysis
 
See Part II, Item 7, “Management’s Discussion and Analysis – Legal and Regulatory Matters,” for information on various legal proceedings, including but not limited to:
 
  •   The U.S. patent litigation involving Zyprexa, Evista, Gemzar, and Xigris
 
  •   The civil investigation by the U.S. Attorney for the Eastern District of Pennsylvania relating to our U.S. sales, marketing, and promotional practices
 
  •   The Zyprexa product liability and related litigation, including claims brought on behalf of healthcare payors
 
  •   The suits we have filed against several of our product liability insurance carriers with respect to our coverage for the Zyprexa product liability claims
 
That information is incorporated into this Item by reference.
 

EXCERPTS ON THIS PAGE:

10-K
Feb 22, 2010
10-K (2 sections)
Feb 27, 2009
10-K (2 sections)
Oct 21, 2008
10-K (2 sections)
Feb 29, 2008
10-K
Feb 28, 2007

RELATED TOPICS for LLY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki